Company Overview

Anixa Biosciences, Inc. is a U.S.-based biotechnology company focused on the development of novel cancer therapies and preventive vaccines. The company operates within the biotechnology and oncology industries and is primarily engaged in early-stage research and clinical development rather than commercial product sales. Anixa’s core programs are centered on immuno-oncology, including therapeutic cancer vaccines and chimeric antigen receptor T-cell (CAR‑T) therapies, with a strategic emphasis on cancers that represent significant unmet medical needs.

The company’s principal development programs include a breast cancer vaccine targeting α‑lactalbumin and an ovarian cancer CAR‑T therapy targeting the follicle-stimulating hormone receptor (FSHR). Anixa does not currently generate material operating revenue and relies on equity financing and strategic collaborations to fund operations. Its competitive positioning is based on exclusive licenses to intellectual property developed by major academic institutions, particularly the Cleveland Clinic, providing access to differentiated science and clinical expertise. Anixa traces its corporate origins to earlier pharmaceutical entities and adopted its current name in 2015 as it refocused exclusively on oncology and immunotherapy.

Business Operations

Anixa operates as a single-reportable segment focused on oncology research and development, with activities spanning preclinical research, clinical trials, regulatory preparation, and intellectual property management. The company’s operations are largely conducted through outsourced research, clinical trial sites, and academic collaborations rather than internal manufacturing or large-scale laboratory infrastructure. Its development pipeline includes both therapeutic and preventive approaches to cancer, distinguishing it from many oncology peers focused solely on treatment.

The company’s most significant operational relationship is with Cleveland Clinic, through which Anixa holds exclusive licenses to multiple cancer immunotherapy technologies. These collaborations provide access to clinical trial execution, scientific leadership, and ongoing research support. Anixa currently conducts its operations primarily in the United States and does not report material international revenue-generating activities. As a development-stage company, its expenditures are primarily related to research and development, clinical trials, and general corporate administration.

Strategic Position & Investments

Anixa’s strategic direction is centered on advancing first-in-class immunotherapies with the potential for broad clinical impact and long-term value creation. Key growth initiatives include the continued clinical development of its breast cancer vaccine program and ovarian cancer CAR‑T program, both of which are designed to address cancers with high mortality rates and limited preventive or therapeutic options. The company emphasizes preventive oncology as a long-term strategic differentiator, particularly through its vaccine platform.

Rather than pursuing large-scale acquisitions, Anixa’s investment strategy has focused on licensing and developing academic-originated intellectual property. Its portfolio consists primarily of licensed technologies rather than wholly owned subsidiaries or operating businesses. The company has also explored infectious disease vaccine applications using similar immunologic principles, though oncology remains its core strategic priority. All programs are subject to clinical, regulatory, and financing risks inherent in early-stage biotechnology development.

Geographic Footprint

Anixa Biosciences is headquartered in San Jose, California, and its corporate operations are primarily based in the United States. The company’s research and clinical development activities are largely conducted through U.S.-based academic and clinical institutions, with Cleveland Clinic in Ohio representing a central hub for its licensed technologies and ongoing trials.

While Anixa does not maintain a significant physical presence outside the United States, its intellectual property strategy and potential future commercialization pathways are intended to support global markets. Any international footprint is currently indirect, occurring through clinical research standards, regulatory planning, and prospective licensing or commercialization arrangements rather than owned facilities or subsidiaries abroad.

Leadership & Governance

Anixa is led by a management team with experience in biotechnology, oncology, and corporate finance, with governance oversight provided by its board of directors. The company’s leadership emphasizes disciplined capital management, scientific validation, and collaboration with leading research institutions as core elements of its operating philosophy and long-term strategy.

Key executives include:

• Dr. Amit Kumar – Chairman and Chief Executive Officer
• Dr. Joseph Hernandez – Chief Medical Officer
• Michael Catelani – Chief Financial Officer

The leadership team’s strategic vision is focused on advancing high-impact immunotherapies through clinical milestones while preserving shareholder value in a capital-intensive development environment. Where executive role details vary across public disclosures, data is presented based on the most consistently reported information; any discrepancies are inconclusive based on available public sources.